Taiga Biotechnologies, Inc. is developing a new class of cell-based therapies utilizing autologous immune cells and allogeneic stem cells 

Our Technology

  • Specific target NOT required

  • No genetic modification

  • No expansion of cells

  • 4-hour manufacturing process

  • Scalable, Reliable, Low Risk

Upcoming Milestones

  • TBX-3400 clinical trials

    • Phase 1/2 data for melanoma​

    • Phase 1/2 data for solid tumors

    • Phase 2 initiation for hepatitis B

  • TBX-2400 clinical trial

    • Phase 1/2 data for bone marrow transplants​